华润系再“瘦身”，华润医药14.2亿出售天麦生物科技股权

Core Viewpoint - China Resources Pharmaceutical Group Limited (referred to as "China Resources Pharmaceutical") announced the potential sale of approximately 17.87% equity in Hefei Tianmai Biotechnology Development Co., Ltd. (referred to as "Tianmai Biotechnology") through public listing, with a base price of approximately 1.42 billion yuan [1] Group 1: Company Actions - China Resources Pharmaceutical's wholly-owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., has initiated the sale of its stake in Tianmai Biotechnology [1] - The company holds a total of 23.75% equity in Tianmai Biotechnology, with China Resources Pharmaceutical Investment being the largest shareholder at 20% [2] Group 2: Industry Context - The sale is seen as a strategic move to focus on core business by divesting non-core assets, influenced by the failure of Tianmai Biotechnology's oral insulin product to gain market approval [3] - Tianmai Biotechnology's application for the oral insulin capsule (ORMD-0801) was not approved by the National Medical Products Administration, impacting its market position [3] Group 3: Financial Performance - Since 2025, China Resources has been actively selling its pharmaceutical assets, indicating a shift in strategic direction [4] - In 2024, China Resources Pharmaceutical reported revenue of approximately 257.7 billion yuan, a year-on-year increase of 5.3%, but a net profit decline of 13.06% to approximately 3.351 billion yuan [4] - For the first half of 2025, revenue was approximately 131.9 billion yuan, a year-on-year increase of 2.54%, while net profit fell by 20.30% to approximately 2.077 billion yuan [4]